capital · May 16, 2026
Q1 2026 Biotech Funding Paradox Shows Volume Leaders Versus Value Leaders
Share the canonical public link.
Venture firms reported a Q1 funding paradox with volume leaders versus value leaders. Active private biotech investors placed 65 percent of investments into new portfolio companies. Biopharma acquisitions reached more than $31 billion in Q1 2026. William Blair bankers issued the quarterly report. The divergence defined the venture landscape in April 2026.
Spend governor blocked model creation: provider_circuit_open (lane=dev, provider=together)